The Metabolomics Service shared resource (Metabolomics) of the Rutgers Cancer Institute of New Jersey (CINJ) is a Cancer Center managed shared resource whose purpose is to enable state-of-the-art analysis of cancer metabolism. The past decade has seen a surge of interest in tumor metabolism, driven by the recognition that oncogenes up-regulate metabolism and that certain metabolites can themselves cause cancer (?oncometabolites?). The discovery of the best-established oncometabolite, 2-hydroxyglutarate, involved a central contribution from Joshua Rabinowitz, Director of this Metabolomics shared resource. The shared resource?s mission is two-fold: 1) to continue to push the frontiers of tumor metabolism measurement, enabling additional such scientific discoveries that significantly impact cancer diagnosis and therapy and 2) to provide CINJ members with easy, cost-effective access to these capabilities, thereby enhancing productivity across the consortium. To this end, the shared resource provides access to basic metabolism measurement capabilities, like oxygen consumption, which involve instruments that are readily shared (e.g., Seahorse). It also provides more advanced services, such as large-scale quantitative metabolite measurement by LC-MS. In addition, it develops and collaboratively applies cutting-edge metabolism measurement capabilities that are unique or available in only a handful of institutions world-wide (e.g. quantitative analysis of tumor-host metabolic interplay in vivo using isotope tracers). Building from informal collaborations that started in 2011, the consortium cancer center, with support from CCSG Developmental Funds, established a CCSG-supported developing shared resource for Metabolomics. This shared resource involved substantial investments by both Rutgers and Princeton Universities, in the form of multiple instruments purchased by each university. This shared resource not only met the existing need for metabolic analysis, but also encouraged investigators, through a variety of programmatic platforms, to pursue cancer metabolism research. MSR, Page 1 of 1; DRAFT 1/18/18 8:28 AM !

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA072720-22
Application #
10112866
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-03-01
Project End
2024-02-29
Budget Start
2021-03-01
Budget End
2022-02-28
Support Year
22
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Rbhs -Cancer Institute of New Jersey
Department
Type
DUNS #
078728091
City
New Brunswick
State
NJ
Country
United States
Zip Code
08901
Deek, Matthew P; Kim, Sinae; Ahmed, Inaya et al. (2018) Prognostic Impact of Missed Chemotherapy Doses During Chemoradiation Therapy for Non-Small Cell Lung Cancer. Am J Clin Oncol 41:362-366
O'Malley, Denalee; Dewan, Asa A; Ohman-Strickland, Pamela A et al. (2018) Determinants of patient activation in a community sample of breast and prostate cancer survivors. Psychooncology 27:132-140
Park, Kihan; Chen, Wenjin; Chekmareva, Marina A et al. (2018) Electromechanical Coupling Factor of Breast Tissue as a Biomarker for Breast Cancer. IEEE Trans Biomed Eng 65:96-103
Jang, Thomas L; Patel, Neal; Faiena, Izak et al. (2018) Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer. Cancer 124:4010-4022
Gupta, Apar; Ohri, Nisha; Haffty, Bruce G (2018) Hypofractionated radiation treatment in the management of breast cancer. Expert Rev Anticancer Ther 18:793-803
Patrizii, Michele; Bartucci, Monica; Pine, Sharon R et al. (2018) Utility of Glioblastoma Patient-Derived Orthotopic Xenografts in Drug Discovery and Personalized Therapy. Front Oncol 8:23
Herman, Joseph M; Jabbour, Salma K; Lin, Steven H et al. (2018) Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation. Pancreas 47:208-212
CeliĆ -Terrassa, Toni; Bastian, Caleb; Liu, Daniel et al. (2018) Hysteresis control of epithelial-mesenchymal transition dynamics conveys a distinct program with enhanced metastatic ability. Nat Commun 9:5005
Zloza, Andrew (2018) Viruses, bacteria, and parasites - oh my! a resurgence of interest in microbial-based therapy for cancer. J Immunother Cancer 6:3
Paratala, Bhavna S; Chung, Jon H; Williams, Casey B et al. (2018) RET rearrangements are actionable alterations in breast cancer. Nat Commun 9:4821

Showing the most recent 10 out of 775 publications